Figure 2.

Murine FUTCs show treatment-adaptive signaling mechanisms

(A) Graphic model for subtype-selective adaptive activation of MAPK and PI3K-AKT pathways in murine Kras mutant NSCLC cultures.

(B) Dose-response curves of FUTCs and CR cultures treated trametinib (TR), afatinib (AF), and combination treatment. For the combination screen, 5 nM TR was used together with a dose series of AF.

(C) DSS calculated for (B) and compared between KL and KP subtypes for both FUTCs and CR cultures.

(D) Immunoblots of KL and KP FUTCs treated with vehicle (C; DMSO) and or treated with 50 nM TR for various time points (4, 24, 48, and 72 h), and probed with indicated antibodies.

Error bars represent ±SEMs. Student’s t test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.